Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

RCEL vs XTNT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RCEL
AVITA Medical, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$135M
5Y Perf.-86.3%
XTNT
Xtant Medical Holdings, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$81M
5Y Perf.-53.1%

RCEL vs XTNT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RCEL logoRCEL
XTNT logoXTNT
IndustryMedical - DevicesMedical - Devices
Market Cap$135M$81M
Revenue (TTM)$72M$133M
Net Income (TTM)$-49M$2M
Gross Margin82.1%62.0%
Operating Margin89.0%4.8%
Total Debt$2M$35M
Cash & Equiv.$10M$6M

RCEL vs XTNTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RCEL
XTNT
StockMay 20May 26Return
AVITA Medical, Inc. (RCEL)10013.7-86.3%
Xtant Medical Holdi… (XTNT)10046.9-53.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: RCEL vs XTNT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: XTNT leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
RCEL
AVITA Medical, Inc.
The Long-Run Compounder

RCEL is the clearest fit if your priority is long-term compounding.

  • -57.1% 10Y total return vs XTNT's -97.6%
Best for: long-term compounding
XTNT
Xtant Medical Holdings, Inc.
The Income Pick

XTNT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.69
  • Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
  • Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthXTNT logoXTNT28.4% revenue growth vs RCEL's 11.5%
Quality / MarginsXTNT logoXTNT1.3% margin vs RCEL's -67.8%
Stability / SafetyXTNT logoXTNTBeta 0.69 vs RCEL's 1.83
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)XTNT logoXTNT+13.5% vs RCEL's -52.0%
Efficiency (ROA)XTNT logoXTNT1.8% ROA vs RCEL's -86.2%, ROIC -12.8% vs 8.2%

RCEL vs XTNT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RCELAVITA Medical, Inc.
FY 2025
Lease Revenue
100.0%$731,000
XTNTXtant Medical Holdings, Inc.
FY 2024
Orthobiologics
56.6%$66M
Spinal Implant
42.1%$49M
License Revenue
1.3%$2M

RCEL vs XTNT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLXTNTLAGGINGRCEL

Income & Cash Flow (Last 12 Months)

XTNT leads this category, winning 4 of 6 comparable metrics.

XTNT is the larger business by revenue, generating $133M annually — 1.9x RCEL's $72M. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to RCEL's -67.8%. On growth, XTNT holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
RevenueTrailing 12 months$72M$133M
EBITDAEarnings before interest/tax$64M$11M
Net IncomeAfter-tax profit-$49M$2M
Free Cash FlowCash after capex-$31M$5M
Gross MarginGross profit ÷ Revenue+82.1%+62.0%
Operating MarginEBIT ÷ Revenue+89.0%+4.8%
Net MarginNet income ÷ Revenue-67.8%+1.3%
FCF MarginFCF ÷ Revenue-43.6%+3.9%
Rev. Growth (YoY)Latest quarter vs prior year-4.3%+19.0%
EPS Growth (YoY)Latest quarter vs prior year+15.9%+123.7%
XTNT leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

XTNT leads this category, winning 2 of 2 comparable metrics.
MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
Market CapShares × price$135M$81M
Enterprise ValueMkt cap + debt − cash$127M$110M
Trailing P/EPrice ÷ TTM EPS-2.54x-4.81x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple1.99x
Price / SalesMarket cap ÷ Revenue1.89x0.69x
Price / BookPrice ÷ Book value/share1.80x
Price / FCFMarket cap ÷ FCF
XTNT leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

RCEL leads this category, winning 5 of 6 comparable metrics.

On the Piotroski fundamental quality scale (0–9), RCEL scores 3/9 vs XTNT's 2/9, reflecting mixed financial health.

MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
ROE (TTM)Return on equity+3.8%
ROA (TTM)Return on assets-86.2%+1.8%
ROICReturn on invested capital+8.2%-12.8%
ROCEReturn on capital employed+2.4%-17.9%
Piotroski ScoreFundamental quality 0–932
Debt / EquityFinancial leverage0.82x
Net DebtTotal debt minus cash-$8M$29M
Cash & Equiv.Liquid assets$10M$6M
Total DebtShort + long-term debt$2M$35M
Interest CoverageEBIT ÷ Interest expense1.55x
RCEL leads this category, winning 5 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

XTNT leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in XTNT five years ago would be worth $3,395 today (with dividends reinvested), compared to $2,284 for RCEL. Over the past 12 months, XTNT leads with a +13.5% total return vs RCEL's -52.0%. The 3-year compound annual growth rate (CAGR) favors XTNT at -3.9% vs RCEL's -34.9% — a key indicator of consistent wealth creation.

MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
YTD ReturnYear-to-date+27.4%-23.1%
1-Year ReturnPast 12 months-52.0%+13.5%
3-Year ReturnCumulative with dividends-72.4%-11.2%
5-Year ReturnCumulative with dividends-77.2%-66.1%
10-Year ReturnCumulative with dividends-57.1%-97.6%
CAGR (3Y)Annualised 3-year return-34.9%-3.9%
XTNT leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

XTNT leads this category, winning 2 of 2 comparable metrics.

XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than RCEL's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTNT currently trades 60.7% from its 52-week high vs RCEL's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
Beta (5Y)Sensitivity to S&P 5001.83x0.69x
52-Week HighHighest price in past year$9.85$0.95
52-Week LowLowest price in past year$3.22$0.44
% of 52W HighCurrent price vs 52-week peak+44.9%+60.7%
RSI (14)Momentum oscillator 0–10045.261.8
Avg Volume (50D)Average daily shares traded205K143K
XTNT leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricRCEL logoRCELAVITA Medical, In…XTNT logoXTNTXtant Medical Hol…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$6.75
# AnalystsCovering analysts7
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

XTNT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). RCEL leads in 1 (Profitability & Efficiency).

Best OverallXtant Medical Holdings, Inc. (XTNT)Leads 4 of 6 categories
Loading custom metrics...

RCEL vs XTNT: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is RCEL or XTNT a better buy right now?

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 11. 5% for AVITA Medical, Inc. (RCEL). Analysts rate AVITA Medical, Inc. (RCEL) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — RCEL or XTNT?

Over the past 5 years, Xtant Medical Holdings, Inc.

(XTNT) delivered a total return of -66. 1%, compared to -77. 2% for AVITA Medical, Inc. (RCEL). Over 10 years, the gap is even starker: RCEL returned -57. 1% versus XTNT's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — RCEL or XTNT?

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 69β versus AVITA Medical, Inc. 's 1. 83β — meaning RCEL is approximately 165% more volatile than XTNT relative to the S&P 500.

04

Which is growing faster — RCEL or XTNT?

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus 11. 5% for AVITA Medical, Inc. (RCEL). Over a 3-year CAGR, XTNT leads at 28. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — RCEL or XTNT?

Xtant Medical Holdings, Inc.

(XTNT) is the more profitable company, earning -14. 0% net margin versus -67. 8% for AVITA Medical, Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCEL leads at 89. 0% versus -10. 3% for XTNT. At the gross margin level — before operating expenses — RCEL leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — RCEL or XTNT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is RCEL or XTNT better for a retirement portfolio?

For long-horizon retirement investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). AVITA Medical, Inc. (RCEL) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTNT: -97. 6%, RCEL: -57. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between RCEL and XTNT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RCEL is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

RCEL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 49%
Run This Screen
Stocks Like

XTNT

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 37%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RCEL and XTNT on the metrics below

Revenue Growth>
%
(RCEL: -4.3% · XTNT: 19.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.